BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for March:

March 2-3

RBC Capital Markets Healthcare Conference

March 4

Bristol-Myers Squibb investor/analyst meeting ( BMY)

March 5-7

ASCO Genitourinary Cancers Symposium: Dendreon ( DNDN) presenting updated data from the phase III study of Provenge

March 8-11

Cowen & Co Healthcare Conference

March 9

FDA advisory panel meets to discuss InterMune's ( ITMN) pirfenidone for the treatment of idiopathic pulmonary fibrosis. The FDA's briefing documents for this meeting likely available on March 5 or March 8.

March 12

FDA approval decision date for exenatide once weekly for diabetes, developed by Amylin Pharmaceuticals ( AMLN) and Alkermes ( ALKS), co-marketed by Eli Lilly ( LLY).

March 14-16

American College of Cardiology annual meeting

March 19

Viropharma ( VPHM) investor/analyst meeting

If you liked this article you might like


Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio